CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl

International Journal of Cancer

Volumn 119, Issue 11, 2006, Pages 2520-2526

  Nakajima, Miki ^a   Itoh, Masahiro ^a   Sakai, Haruko ^a   Fukami, Tatsuki ^a   Katoh, Miki ^a   Yamazaki, Hiroshi ^a,d   Kadlubar, Fred F ^b   Imaoka, Susumu ^c,e   Funae, Yoshihiko ^c   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b National Center for Toxicology Research   (United States)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^e KWANSEI GAKUIN UNIVERSITY   (Japan)

Author keywords

4 aminobiphenyl; Bladder cancer; Cytochrome P450; Metabolic activation

Indexed keywords

4 BIPHENYLAMINE; ANTIBODY; FLUVOXAMINE; MESSENGER RNA; METHOXSALEN; OXYGENASE; RECOMBINANT ENZYME;

ARTICLE; BLADDER CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ESCHERICHIA COLI; GENOTOXICITY; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME; METABOLIC ACTIVATION; MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINOBIPHENYL COMPOUNDS; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; BIOTRANSFORMATION; DNA PRIMERS; HUMANS; MICROSOMES; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; URINARY BLADDER;

EID: 33750608093     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22136     Document Type: Article

References (42)

1. Fernandez-Salguero P, Gonzalez FJ. The CYP2A gene subfamily, species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 1995;5:S123-S128.
2. Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorti M, Saranen A, Anttila S, Fernandez-Salguero P, Gonzalez FJ, Raunio H. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 1999;57:1407-13.
3. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone. Cancer Res 2000;60:5074-9.
4. Bao Z, He XY, Ding X, Prabhu S, Hong JY. Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos 2005;33:258-61.
5. Clayson DB. Specific aromatic amines as occupational bladder carcinogens. Natl Cancer Inst Monogr 1981;58:15-19.
6. Butler MA, Guengerich FP, Kadlubar FF. Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4′-methylene-bis(2-chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases. Cancer Res 1989;49:25-31.
7. PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989;86: 7696-700.
8. Hammons GJ, Milton D, Stepps K, Guengerich FP, Tukey RH, Kadlubar FF. Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. Carcinogenesis 1997;18:851-4.
9. Kimura S, Kawabe M, Ward JM, Morishima H, Kadlubar FF, Hammons GJ, Femandez-Salguero P, Gonzalez FJ. CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice. Carcinogenesis 1999;20:1825-30.
10. Tsuneoka Y, Dalton TP, Miller ML, Clay CD, Shertzer HG, Talaska G, Medvedovic M, Nebert DW. 4-Aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cypla2(-/-) and Cypla2(+/+) mice. J Natl Cancer Inst 2003;95:1227-37.
11. Iwanari M, Nakajima M, Kizu R, Hayakawa K, Yokoi T. Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. Arch Toxicol 2002;76:287-98.
12. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, Yokoi T. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 2004;64:3119-25.
13. Imaoka S, Yoneda Y, Sugimoto T, Hiroi T, Yamamoto K, Nakatani T, Funae Y. CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem Biophys Res Commun 2000;277:776-80.
14. 5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 2000;24:329-37.
15. Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, Yokoi T. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 2004;76:519-27.
16. Yamanaka H, Nakajima M, Fukami T, Sakai H, Nakamura A, Katoh M, Takamiya M, Aoki Y, Yokoi T. CYP2A6 and CYP2B6 are involved in nomicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos 2005;33: 1811-18.
17. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 1964;239:2370-8.
18. Williams CH, Jr, Kamin H. Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J Biol Chem 1962;237:587-95.
19. Yasukochi Y, Masters BS. Some properties of detergent-solubilized NADPH-cytochrome c (cytochrome F-450) reductase purified by biospecific affinity chromatography. J Biol Chem 1976;251:5337-44.
20. Wang SL, He XY, Hong JY. Human cytochrome p450 2S1: lack of activity in the metabolic activation of several cigarette smoke carcinogens and in the metabolism of nicotine. Drug Metab Dispos 2005;33: 336-40.
21. Pastrakuljic A, Tang BK, Roberts EA, Kalow W. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 1997;53:531-8.
22. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Miners JO. Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics 1994;4:281-4.
23. Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995;23: 154-8.
24. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 2001;29:897-902.
25. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 1997;25:1407-15.
26. von Weymarn LB, Zhang QY, Ding X, Hollenberg PF. Effects of 8-methoxypsoralen on cytochrome. P450 2A13. Carcinogenesis 2005;26: 621-9.
27. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997;282:1608-14.
28. Yamazaki H, Hatanaka N, Kizu R, Hayakawa K, Shimada N, Guengerich FP, Nakajima M, Yokoi T. Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1. Mutat Res 2000; 472:129-38.
29. Ding S, Lake BG, Friedberg T, Wolf CR. Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem J 1995;306: 161-6.
30. Bièche I, Girault I, Urbain E, Tozlu S, Lidereau R. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor α-positive postmenopausal breast carcinoma. Breast Cancer Res 2004;6:R252-R263.
31. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990;29:1322-9.
32. Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, Yokoi T. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 1999;27:1381-91.
33. Nakajima M, Kobayashi K, Oshima K, Shimada N, Tokudome S, Chiba K, Yokoi T. Activation of phenacetin O-deethylase activity by α-naphthoflavone in human liver microsomes. Xenobiotica 1999;29: 885-98.
34. Kobayashi K, Nakajima M, Oshima K, Shimada N, Yokoi T, Chiba K. Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos 1999; 27:860-5.
35. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabi B, Ilett KF, Kadlubar FF. N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun 1992;185:839-44.
36. Oda Y. Analysis of the involvement of human N-acetyltransferase 1 in the genotoxic activation of bladder carcinogenic arylamines using a SOS/umu assay system. Mutat Res 2004;554:399-406.
37. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 1995; 55:5230-7.
38. Hoffman SM, Nelson DR, Keeney DS. Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 2001;11:687-98.
39. Rylander T, Neve EP, Ingelman-Sundberg M, Oscarson M. Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). Biochem Biophys Res Commun 2001;281:529-35.
40. Saarikoski ST, Wikman HA, Smith G, Wolff CH, Husgafvel-Pursiainen K. Localization of cytochrome P450 CYP2S1 expression in human tissues by in situ hybridization and immunohistochemistry. J Histochem Cytochem 2005;53:549-56.
41. Smith G, Wolf CR, Deeni YY, Dawe RS, Evans AT, Comrie MM, Ferguson J, Ibbotson SH. Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 2003;361:1336-43.
42. Karlgren M, Miura S, Ingelman-Sundberg M. Novel extrahepatic cytochrome P450s. Toxicol Appl Pharmacol 2005;207:57-61.